Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids

Cortico Atrophy Clinical Trial

Official title:

Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00709579
• Other study ID #: MODULCORTICOATROPHIE
• Secondary ID: 2007-A00675-48
• Status: Active, not recruiting
• Phase: Phase 3
• First received: June 30, 2008
• Last updated: July 3, 2008
• Start date: June 2008
• Est. completion date: August 2010

Study information

• Verified date: July 2008
• Source: Pierre Fabre Dermo Cosmetique
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

Methodology :Phase III study, single centre, double blind, versus excipient, randomised, controlateral design.

Selection of the patients :Number of subjects required 60 :

• 30 patients needing an oral corticotherapy

• 30 patients needing a topical corticotherapy

Description:

Study conduct

Two steps for each patient:

1. the first step lasting 3 months : assessment of changes in mechanisms involved in ACIC with the RV3391A cream (M0 à M3). At the beginning of the corticotherapy, each patient will apply RV3391A on anterior side of a forearm and the placebo on the other side (randomised) for 3 months.

Clinical exam and objective measurements will be realised.

This step will allow us to describe and compare the evolution of cutaneous atrophy's markers produced by glucocorticoïds markers between M0 and M3:

• between topical and oral corticotherapy

• between RV3391A and the placebo.

2. the second step, the cohort follow-up, leading off the end of the first step (M3 à M24) The period of the second step will depend on the progression of patient's disease and on the period of his medical follow-up. This period may lasting until the 24th month after the inclusion in the study.

The patients will not apply RV3391A and the placebo anymore. They will be followed-up in the CHU.Assessments of the cutaneous atrophy's markers produced by glucocorticoïds will be realised at M6, M12, M18 and M24 with non invasive methods (clinical scoring, imaging, extensometry) to exactly describe on a long-term period the evolution of the ACIC. The assessments on forearm having received the placebo will allow us to know natural history of skin atrophy induced by corticotherapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: August 2010
• Est. primary completion date: August 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Patients needing an oral corticotherapy:

• aged over 50 years

• first corticotherapy over 0.5 mg/kg/day

• expectable period with a corticotherapy over 10 mg/day more than 3 months

• having signed a written informed consent form

• registered with a social security or health insurance system

• Patients needing a topical corticotherapy:

• aged over 50 years

• topical corticotherapy with a high or very high potency corticoid over 10 g/day

• expectable period with a topical corticotherapy more than 3 months

• having signed a written informed consent form

• registered with a social security or health insurance system

Exclusion Criteria:

• Oral or topical corticotherapy within the last 3 months

• Cutaneous inflammation on the anterior side of the forearm

• Medical history of psychosis induced by corticotherapy

• Medical history of allergy to RV3391A product its and excipients.

• Medical history of allergy to mineral cream Avene SPF50 excipients.

• Medical history of allergy to latex, surgical tape, chlorhexidine, lidocaine or xylocaine

• Clotting disorder or anticoagulant intake

• Healing disorder

• Women who are not post-menopausal women

• Substitutive estrogenotherapy for less than 6 months

• Impossibility to be registered in the Volunteers National Register

• Inability to comply with requirements of the clinical monitoring program,

• Inability to personally sign the informed consent form

• Is deprived of his freedom by an administrative or judicial decision; or who is under guardianship or protective custody

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Atrophy
• Cortico Atrophy

Intervention

Drug:
• RV3391A
A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
• Placebo
placebo

Locations

Country	Name	City	State
France	Centre Hopitalier Universitaire de Toulouse	Toulouse

Sponsors (5)

Lead Sponsor	Collaborator
Pierre Fabre Dermo Cosmetique	Centre Européen de Recherche sur la Peau,, Paul Sabatier University, Pierre Fabre BIOMETRIE, University Hospital, Geneva

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	20 Mhz echography : Dermal Thickness		M0 versus M3	No
Secondary	20 Mhz echography : Dermal Thickness		M0 versus M6, M12, M18, M24	No
Secondary	Optical Coherent Tomography : Epidermal Thickness		M0, M1, M3, M6, M12, M18, M24	No
Secondary	Frosch Score		M0, M1, M3, M6, M12, M18, M24	No
Secondary	Cutometry: assessment of the skin mechanical properties		M0, M1, M3, M6, M12, M18, M24	No
Secondary	Histology: study of skin layers and assessment of collagen and other proteins.		M0, M3	No
Secondary	Immunohistology and molecular biology: assessment of CD44, HB-EGF and erbB1, cutaneous cytokines, filaggrin, corneodesmosin and involucrin.		M0, M3	No
Secondary	Peeling with an adhesive tape: sample of superficial epidermis layers and assessment by biochemical and immunodetection methods of anti-desmoglein, anti-kallikrein 7 and anti-corneodesmosin antibodies		M0, M3,	No